Institutional & Family Asset Management’s Charles River Laboratories CRL Stock Holding History

Institutional & Family Asset Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$34.3K	Sell	166 -4	-2%	-$906	0.01%	282
2024 Q1	$46.1K	Sell	170 -9	-5%	-$2.15K	0.01%	242
2023 Q4	$42.3K	Sell	179 -2	-1%	-$393	0.01%	251
2023 Q3	$35.5K	Hold	181	–	–	0.01%	246
2023 Q2	$38.1K	Buy	181 +22	+14%	+$4.38K	0.01%	247
2023 Q1	$32.1K	Sell	159 -1	-0.6%	-$227	0.01%	254
2022 Q4	$34.9K	Buy	160 +7	+5%	+$1.53K	0.01%	252
2022 Q3	$30K	Hold	153	–	–	0.01%	266
2022 Q2	$33K	Buy	153 +28	+22%	+$6.84K	0.01%	260
2022 Q1	$35K	Buy	125 +19	+18%	+$5.86K	0.01%	287
2021 Q4	$40K	Buy	+106	New	+$41.2K	0.01%	287
2019 Q4	–	Sell	-14	Closed	-$2K	–	860
2019 Q3	$2K	Sell	14 -15	-52%	-$2.01K	﹤0.01%	681
2019 Q2	$4K	Buy	29 +24	+480%	+$3.25K	﹤0.01%	616
2019 Q1	$1K	Buy	+5	New	+$657	﹤0.01%	778

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Institutional & Family Asset Management's CRL Position: Q2 2024 in Review

Institutional & Family Asset Management reduced its Charles River Laboratories (CRL) stake by 2.4% in Q2 2024, selling an estimated $906 and leaving 166 shares worth $34.3K. The position accounts for 0.01% of the portfolio, ranked #282.

Institutional & Family Asset Management first reported a position in CRL in Q1 2019 and has held it in 14 quarters since. The position peaked at $46.1K in Q1 2024. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

Institutional & Family Asset Management held 166 shares of Charles River Laboratories worth $34.3K as of Q2 2024.
Institutional & Family Asset Management sold 4 Charles River Laboratories shares in Q2 2024, an estimated $906.
Charles River Laboratories made up 0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #282 holding.
Institutional & Family Asset Management first reported a position in Charles River Laboratories in Q1 2019 and has held it in 14 quarters since.
Institutional & Family Asset Management's Charles River Laboratories position peaked at $46.1K in Q1 2024.
665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.